The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy

Current Drug Metabolism

Volumn 12, Issue 8, 2011, Pages 713-721

  Azzariti, Amalia ^a   Porcelli, Letizia ^a   Quatrale, Anna Elisa ^a   Silvestris, Nicola ^a   Paradiso, Angelo ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Cancer; CYP450; Glycoprotein P; Platinum compounds; Resistance to chemotherapy; Tyrosine kinase inhibitors

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEFITINIB; GLYCOPROTEIN P; IFOSFAMIDE; IMATINIB; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAMOXIFEN; TENIPOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELLULAR DISTRIBUTION; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TISSUE DISTRIBUTION;

EID: 80052255469     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798357042     Document Type: Review

References (110)

1. Krishna, R.; Mayer, L.D. Multidrug resistance (MDR) in cancer.Mechanisms, reversal using modulators of MDR and the role ofMDR modulators in influencing the pharmacokinetics of anticancerdrugs. Eur. J. Pharm. Sci., 2000, 11(4), 265-283
2. Gasparini, G.; Pozza, F.; Harris, A.L. Evaluating the potential usefulnessof new prognostic and predictive indicators in nodenegativebreast cancer patients. J. Natl. Cancer Inst., 1993, 85,1206-1219. (Pubitemid 23223526)
3. Kissel, J.; Brix, G.; Bellemann, M.E.; Strauss, L.G.; Dimitrakopoulou-Strauss, A.; Port, R.; Haberkorn, U.; Lorenz, W.J. Pharmacokineticanalysis of 5-[18F]fluorouracil tissue concentrations measuredwith positron emission tomography in patients with liver metastasesfrom colorectal adenocarcinoma. Cancer Res., 1997, 57,3415-3423. (Pubitemid 27355486)
4. Concato, J.; Feinstein, A.R.; Holford, T.R. The risk of determiningrisk with multivariable models. Ann. Intern. Med., 1993, 118, 201-210.
5. Simon, R.; Altman, D.G. Statistical aspects of prognostic factorstudies in oncology. Br. J. Cancer, 1994, 69, 979-985. (Pubitemid 24161844)
6. McFadyen, M.C.; Melvin, W.T.; Murray, G.I. Cytochrome P450enzymes: novel options for cancer therapeutics. Mol. Cancer Ther.,2004, 3(3), 363-371. (Pubitemid 39193712)
7. Conley, A.; Hinshelwood, M. Mammalian aromatases. Reproduction,2001, 121, 685-695 (Pubitemid 32472054)
8. Capdevilla, J.H.; Flack, J.R.; Eastabrook, R.W. Cytochrome P450and the arachidonate cascade. FASEB J, 1992, 6, 731-736.
9. Azzariti, A.; Porcelli, L.; Paradiso, A. In: Multi-drug resistance:biological and pharmaceutical advance in the antitumour treatment,Colabufo, N.A., Ed.; Research SignPost. 37/661 (2), Kerala,India, 2008; pp. 1-18.
10. Marquez, B.; Van Bambeke, F. ABC Multidrug Transporters: Targetfor Modulation of Drug Pharmacokinetics and Drug-Drug Interactions.Curr. Drug Targets., 2010, Nov 2 [Epub ahead of print].
11. Hamid, O. Emerging treatments in oncology: focus on tyrosinekinase (erbB) receptor inhibitors. J. Am. Pharm. Assoc. (Wash DC),2004, 44, 52-58.
12. Ipatova, O.M.; Torkhovskaya, T.I.; Medvedeva, N.V.; Prozorovsky,V.N.; Ivanova, N.D.; Shironin, A.V.; Baranova, V.S.; Archakov,A.I. Bioavailability of Oral Drugs and the Methods for ItsImprovement. Biochemistry (Moscow) supplement series B: BiomadocalChemistry, 2010, 4(1), 82-94.
13. Pang, K.S. Modeling of intestinal drug absorption: roles of transportersand metabolic enzymes (for the Gillette Review Series).Drug Metab. Dispos., 2003, 31, 1507-1519. (Pubitemid 37466919)
14. Cao, X.; Gibbs, S.T.; Fang, L.; Miller, H.A.; Landowski, C.P.;Shin, H.C.; Lennernas, H.; Zhong, Y.; Amidon, G.L.; Yu, L.X.;Sun, D. Why is it challenging to predict intestinal drug absorptionand oral bioavailability in human using rat model. Pharm. Res.,2006, 23, 1675-1686. (Pubitemid 44200529)
15. Kim, I.W.; Booth Genthe, C.; a Ambudkar, S.V. Relationship betweendrugs and functional activity of various mammalian Pglycoproteins(ABCB1). Mini Rev. Med. Chem., 2008, 8, 193-200. (Pubitemid 351611822)
16. Kato, M. Intestinal first-pass metabolism of CYP3A4 substrates.Drug Metab. Pharmacokinet., 2008, 23, 87-94.
17. van de Kerkhof, E.G.; de Graaf, I.A.; Groothuis, G.M. In vitromethods to study intestinal drug metabolism. Curr. Drug Metab.,2007, 8, 658-675. (Pubitemid 47578115)
18. Takara, K.; Ohnishi, N.; Horibe, S.; Yokoyama, T. Expression profilesof drug-metabolizing enzyme CYP3A and drug efflux transportermultidrug resistance 1 subfamily mRNAs in small intestine.Drug Metab. Dispos., 2003, 31, 1235-1239. (Pubitemid 37152974)
19. Shayeganpour, A.; ElKadi, A.O.; Brocks, D.R. Determination ofthe enzyme(s) involved in the metabolism of amiodarone in liverand intestine of rat: The contribution of cytochrome P450 3A isoforms.Drug Metab. Dispos., 2006, 34, 43-50. (Pubitemid 43042645)
20. Chen, K.; Yu, W.P.; Song, L.; and Zhu, Y.M. Quantitative assessmentmodel for gastric cancer screening. World J. Gastroenterol.,2005, 11, 641-644. (Pubitemid 40220750)
21. Guengerich, F.P. Common and uncommon cytochrome P450 reactionsrelated to metabolism and chemical toxicity. Chem. Res.Toxicol., 2001, 14(6), 611-650. (Pubitemid 32565712)
22. Foye, W.O.; Lemke, T.L.; Williams, D.A. Principles of medicinalchemistry, 4th Ed.; Lea & Febiger Book, Philadelphia, 1995.
23. Hollenberg, P.F. Mechanisms of cytochrome P450 and peroxidasecatalyzedxenobiotic metabolism. FASEB J., 1992, 6(2), 686-694.
24. Ortiz de Montellano, P.R. Cytochrome P450 : structure, mechanism,and biochemistry, 2nd ed., Plenum: New York, 1995.
25. Linton, K.J. Structure and function of ABC transporters. Physiology(Bethesda), 2007, 22, 122-130.
26. Ingelman-Sundberg, M.; Sim, S.C.; Gomez, A.; Rodriguez-Antona,C. Influence of cytochrome P450 polymorphisms on drug therapies:pharmacogenetic, pharmacoepigenetic and clinical aspects.Pharmacol. Ther., 2007, 116(3), 496-526. (Pubitemid 350116943)
27. Tang, K.; Wong, L.P.; Lee, E.J.; Chong, S.S.; Lee, C.G. Genomicevidence for recent positive selection at the human MDR1 gene locus.Hum. Mol. Genet., 2004, 13(8), 783-797. (Pubitemid 38515208)
28. Xu, C.; Li, C.Y.; Kong, A.N. Induction of phase I, II and III drugmetabolism/transport by xenobiotics. Arch. Pharm. Res., 2005,28(3), 249-268. (Pubitemid 44698742)
29. Benet, L.Z.; Cummins, C.L.; Wu, C.Y. Unmasking the dynamicinterplay between efflux transporters and metabolic enzymes. Int.J. Pharm., 2004, 277, 3-9. (Pubitemid 38670415)
30. Nwankwo, J.O. Significant transcriptional down-regulation of thehuman MDR1 gene by b-naphthoflavone: A proposed hypothesislinking potent CYP gene induction to MDR1 inhibition. MedicalHypotheses, 2007, 68, 661-669. (Pubitemid 46037957)
31. Hall, P.M.; Stupans, I.; Burgess, W.; Birkett, D.J.; McManus, M.E.Immunohistochemical localization of NADPH-cytochrome P450reductase in human tissues. Carcinogenesis, 1989, 10(3), 521-530. (Pubitemid 19089919)
32. Murray, G.I.; McFadyen, M.C.; Mitchell, R.T.; Cheung, Y.L.;Kerr, A.C.; Melvin, W.T. Cytochrome P450 CYP3A in human renalcell cancer. Br. J. Cancer, 1999, 79, 1836-1842. (Pubitemid 29132313)
33. Murray, G.I.; Taylor, M.C.; McFadyen, M.C.; McKay, J.A.; Greenlee,W.F.; Burke, M.D.; Melvin, W.T. Tumor specific expression ofcytochrome P450 CYP1B1. Cancer Res, 1997, 57, 3026-3031. (Pubitemid 27315056)
34. Murray, G.I.; Foster, C.O.; Barnes, T.S.; Weaver, R.J.; Ewen,S.W.; Melvin, W.T.; Burke, M.D. Expression of cytochrome P450CYP1A1 in breast cancer. Br. J. Cancer, 1991, 63, 1021-1023.
35. Murray, G.I.; McKay, J.A.; Weaver, R.J.; Ewen, S.W.; Melvin,W.T.; Burke, M.D. Cytochrome P450 expression is a common molecularevent in soft tissue sarcomas. J. Pathol, 1993, 171, 49-52. (Pubitemid 23294687)
36. Murray, G.I.; Shaw, D.; Weaver, R.J.; McKay, J.A.; Ewen, S.W.;Melvin, W.T.; Burke, M.D. Cytochrome P450 expression in esophagealcancer. Gut, 1994, 35, 599-603.
37. McFadyen, M.C.E.; Cruickshank, M.E.; Miller, I.D.; McLeod,H.L.; Melvin, W.T.; Haites, N.E.; Parkin, D.; Murray, G.I. CytochromeP450 CYP1B1 over-expression in primary and metastaticovarian cancer. Br. J. Cancer, 2001, 85, 242-246. (Pubitemid 32695746)
38. Gibson, P.; Gill, J.H.; Khan, P.A.; Seargent, J.M.; Martin, S.W.;Batman, P.A.; Griffith, J.; Bradley, C.; Double, J.A.; Bibby, M.C.;Loadman, P.M. Cytochrome P450 1B1 (CYP1B1) is overexpressedin human colon adenocarcinomas relative to normal colon: implicationsfor drug development. Mol. Cancer. Ther, 2003, 2, 527-534.
39. Godoy, W.; Albano, R.M.; Moraes, E.G.; Pinho, P.R.; Nunes, R.A.;Saito, E.H.; Higa, C.; Filho, I.M.; Kruel, C.D.; Schirmer, C.C.;Gurski, R.; Lang, M.A.; Pinto, L.F. CYP2A6/2A7 and CYP2E1expression in human esophageal mucosa: regional and interindividualvariation in expression and relevance to nitrosamine metabolism.Carcinogenesis, 2002, 23, 611-616. (Pubitemid 34498499)
40. Dhaini, H.R.; Thomas, D.G.; Giordano, T.J.; Johnson, T.D.; Biermann,J.S.; Leu, K.; Hollenberg, P.F.; Baker, L.H. CytochromeP450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma.J. Clin. Oncol., 2003, 21, 2481-2485. (Pubitemid 46606328)
41. Choi, C.H. ABC transporters as multidrug resistance mechanismsand the development of chemosensitizers for their reversal. CancerCell Int., 2005, 5, 30.
42. Cordon-Cardo, C.; O'Brien, J.P.; Casals, D.; Rittman-Grauer, L.;Biedler, J.L.; Melamed, M.R.; Bertino, J.R. Multidrugresistancegene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 695-698. (Pubitemid 19037807)
43. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.;Willingham, M.C. Cellular localization of the multidrugresistancegene product P-glycoprotein in normal human tissues. Proc. Natl.Acad. Sci. U.S.A., 1987, 84, 7735-7738.
44. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.;Willingham, M.C. Immunohistochemical localization in normal tissuesof different epitopes in the multidrug transport protein P170:evidence for localization in brain capillaries and crossreactivity ofone antibody with a muscle protein. J. Histochem. Cytochem.,1989, 37, 159-164. (Pubitemid 19039163)
45. van Asperen, J.; Schinkel, A.H.; Beijnen, J.H.; Nooijen, W.J.;Borst, P.; van Tellingen, O. Altered pharmacokinetics of vinblastinein Mdr1a P-glycoprotein-deficient Mice. J. Natl. CancerInst., 1996, 88(14), 994-999. (Pubitemid 26239388)
46. van Asperen, J.; van Tellingen, O.; Tijssen, F.; Schinkel, A.H.;Beijnen, J.H. Increased accumulation of doxorubicin and doxorubicinolin cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J.Cancer, 1999, 79(1), 108-113. (Pubitemid 28566934)
47. Kang, W.; Weiss, M. Influence of P-glycoprotein modulators oncardiac uptake, metabolism, and effects of idarubicin. Pharm. Res.,2001, 18(11), 1535-1541. (Pubitemid 33022408)
48. Weiss, M.; Kang, W. P-glycoprotein inhibitors enhance saturableuptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamicmodeling. J. Pharmacol. Exp. Ther., 2002, 300(2), 688-694.
49. Nakamura, Y.; Ikeda, S.; Furukawa, T.; Sumizawa, T.; Tani, A.;Akiyama, S.; Nagata, Y. Function of P-glycoprotein expressed inplacenta and mole. Biochem. Biophys. Res. Commun., 1997,235(3), 849-853. (Pubitemid 27326573)
50. Ushigome, F.; Takanaga, H.; Matsuo, H.; Yanai, S.; Tsukimori, K.;Nakano, H.; Uchiumi, T.; Nakamura, T.; Kuwano, M.; Ohtani, H.;Sawada, Y. Human placental transport of vinblastine, vincristine,digoxin and progesterone: contribution of P-glycoprotein. Eur. J.Pharmacol., 2000, 408(1), 1-10.
51. Efferth, T.; Osieka, R. Clinical relevance of the MDR1gene and itsgene product, P-glycoprotein, for anticancer chemotherapy: a metaanalysis.Tumordiagn. U. Ther., 1993, 14, 238-243.
52. Neve, E.P.; Ingelman-Sundberg, M. Intracellular transport and localizationof microsomal cytochrome P450. Anal. Bioanal. Chem.,2008, 392(6), 1075-1084.
53. Omura, T. Mitochondrial P450s. Chem. Biol. Interact., 2006, 163,86-93. (Pubitemid 44572220)
54. Willingham, M. C.; Richer, N. D.; Cornwell, M. M.; Tsuruo, T.;Hamada, H.; Gotesman, M. M.; Pastan, I. H. Immunochemical localizationof P170 at the plasma membrane of multidrug-resistanthuman cells. J. Histochem Cytochem., 1987, 35, 1451-1456. (Pubitemid 17165249)
55. Larsen, A.K.; Escargueil, A.E.; Skladanowski, A. Resistancemechanism associated with altered intracellular distribution of anticanceragents. Pharmacol. Ther., 2000, 85, 217-229. (Pubitemid 30160791)
56. Porcelli, L.; Lemos, C.; Peters, G.J.; Paradiso, A.; Azzariti. A. Intracellulartrafficking of MDR transporters and relevance of SNPs.Curr. Top Med. Chem., 2009, 9(2), 197-208.
57. Labroille, G.; Belloc, F.; Bilhou-Nabera, C.; Bonnefille, S.; Bascans,E.; Boisseau, M. R.; Bernard, P.; Lacombe, F. Cytometricstudy of intracellular P-gp expression and reversal of drug resistance.Cytometry, 1998, 32, 86-94. (Pubitemid 28246755)
58. Solazzo, M.; Fantappiè, O.; Lasagna, N.; Sassoli, C.; Nosib, D.;Mazzantia, R. P-gp localization in mitochondria and its functionalcharacterization in multiple drug-resistant cell lines. Exp. Cell Res.,2006, 312, 4070-4078. (Pubitemid 44834517)
59. Maraldi, N. M.; Zini, N.; Santi, S.; Scotlandi, K.; Serra, M.; Baldini,N. P-glycoprotein subcellular localization and cell morphocytein MDR1 gene-transfected human osteosarcoma cell. Biol. Cell,1999, 9, 17-28.
60. Chan, L.M.; Lowes, S.; Hirst, B.H. The ABCs of drug transport inintestine and liver: efflux proteins limiting drug absorption andbioavailability. Eur. J. Pharm. Sci., 2004, 21(1), 25-51. (Pubitemid 38050202)
61. Blumberg, B.; Sabbagh, W.; Juguilon, H.; Bolado, J.; Van Meter,C.M.; Ong, E.S.; Evans, R.M. SXR, a novel steroid and xenobioticsensing nuclear receptor. Gene. Dev., 1998, 12, 3195-3205. (Pubitemid 28496264)
62. Kliewer, S.A.; Moore, J.T.; Wade, L.; Staudinger, J.L.; Watson,M.A.; Jones, S.A.; McKee, D.D.; Oliver, B.B.; Willson, T.M.; Zetterstrom,R.H.; Perlmann, T.; Lehmann, J.M. An orphan nuclearreceptor activated by pregnanes defines a novel steroid signalingpathway. Cell, 1998, 92, 73-82. (Pubitemid 28053299)
63. Lu, T.T.; Repa, J.J.; Mangelsdorf, D.J. Orphan nuclear receptors aseLiXiRs and FiXeRs of sterol metabolism. J. Biol. Chem., 2001,276, 37735-37738.
64. Zhang, H.; Leculyse, E.; Liu, L.; Hu, M.; Matoney, L.; Zhu, W.;Yan, B. Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch. Biochem. Biophys.,1999,368, 14-22. (Pubitemid 29372299)
65. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor responseelements mediate induction of intestinal MDR1 by rifampin. J.Biol. Chem., 2001, 276, 1458-14587.
66. Synold, T.W.; Dussault, I.; Forman, B.M. The orphan nuclear receptorSXR coordinately regulates drug metabolism and efflux.Nat. Med., 2001, 7(5), 584-590. (Pubitemid 32448326)
67. Wacher, V.J.; Wu, C.Y.; Benet, L.Z. Overlapping substratespecificities and tissue distribution of cytochrome P450 3A and Pglycoprotein:implications for drug delivery and activity in cancerchemotherapy. Mol. Carcinog., 1995, 13(3), 129-134.
68. van Schaik, R.H. CYP450 pharmacogenetics for personalizing cancertherapy. Drug Resist. Updat., 2008, 11(3), 77-98.
69. Schuetz, E.G.; Beck, W.T.; Schuetz, J.D. Modulators and substratesof P-glycoprotein and cytochrome P4503A coordinately upregulatethese proteins in human colon carcinoma cells. Mol.Pharmacol., 1996, 49(2), 311-318. (Pubitemid 26066117)
70. Azzariti, A.; Porcelli, L.; Gatti, G.; Nicolin, A.; Paradiso, A. Synergicantiproliferative and antiangiogenic effects of EGFR andmTor inhibitors on pancreatic cancer cells. Biochem. Pharmacol.,2008, 75(5), 1035-1044.
71. Azzariti, A.; Porcelli, L.; Simone, G.M.; Quatrale, A.E.; Colabufo,N.A.; Berardi, F.; Perrone, R.; Zucchetti, M.; D'Incalci, M.; Xu,J.M.; Paradiso, A. Tyrosine kinase inhibitors and multidrug resistanceproteins: interactions and biological consequences. CancerChemother Pharmacol. 2010, 65, 335-346.
72. Azzariti, A.; Porcelli, L.; Xu, J.M.; Simone, G.M.; Paradiso, A.Prolonged exposure of colon cancer cells to the epidermal growthfactor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenicagent ZD6474: Cytotoxic and biomolecular effects. World JGastroenterol., 2006, 12(32), 5140-5147. (Pubitemid 44355909)
73. Azzariti, A.; Xu, J.M.; Porcelli, L.; Paradiso, A. The scheduledependentenhanced cytotoxic activity of 7-ethyl-10- hydroxycamptothecin(SN-38) in combination with Gefitinib (Iressa,ZD1839). Biochem. Pharmacol., 2004, 68(1), 135-144. (Pubitemid 38746549)
74. Giannelli, G.; Azzariti, A.; Fransvea, E.; Porcelli, L.; Antonaci, S.;Paradiso, A. Laminin-5 offsets the efficacy of gefitinib ('Iressa') inhepatocellular carcinoma cells. Br. J. Cancer, 2004, 91(11), 1964-1969. (Pubitemid 40065526)
75. Giannelli, G.; Sgarra, C.; Porcelli, L.; Azzariti, A.; Antonaci, S.;Paradiso, A. EGFR and VEGFR as potential target for biologicaltherapies in HCC cells. Cancer Lett., 2008, 262(2), 257-264.
76. Sebastian, S.; Azzariti, A.; Accardi, R.; Conti, D.; Pilato, B.; LaCalamita,R.; Porcelli, L.; Simone, G.M.; Tommasi, S.; Tommasino,M.; Paradiso, A. Validation of gefitinib effectiveness in a broadpanel of head and neck squamous carcinoma cells. Int. J. Mol.Med., 2008, 21(6), 809-817.
77. Italiano, A.; Besse, B.; Planchard, D.; Soria, J.C. Targeting epidermalgrowth factor receptor in non-small cell lung cancer: currentadvances and perspectives. Bull Cancer, 2007, 94(7 Suppl), F177-188. (Pubitemid 350131942)
78. Carcaboso, .A.M.: Elmeliegy, M.A.; Shen, J.; Juel, S.J.; Zhang,Z.M.; Calabrese, C.; Tracey, L.; Waters, C.M.; Stewart, C.F. Tyrosinekinase inhibitor gefitinib enhances topotecan penetration ofgliomas. Cancer Res., 2010, 70(11), 4499-4508.
79. Kitazaki, T.; Oka, M.; Nakamura, Y.; Tsurutani, J.; Doi, S.; Yasunaga,M.; Takemura, M.; Yabuuchi, H.; Soda, H.; Kohno, S. Gefitinib,an EGFR tyrosine kinase inhibitor, directly inhibits the functionof P-glycoprotein in multidrug resistant cancer cells. LungCancer, 2005, 49(3), 337-343. (Pubitemid 41139146)
80. Noguchi, K.; Kawahara, H.; Kaji, A.; Katayama, K.; Mitsuhashi, J.;Sugimoto, Y. Substrate-dependent bidirectional modulation of Pglycoprotein-mediated drug resistance by erlotinib. Cancer Sci.,2009, 100(9), 1701-1707.
81. de Vries, N.A.; Buckle, T.; Zhao, J.; Beijnen, J.H.; Schellens, J.H.;van Tellingen, O. Restricted brain penetration of the tyrosinekinase inhibitor erlotinib due to the drug transporters P-gp andBCRP. Invest. New Drugs. 2010, [Epub ahead of print].
82. Shi, Z.; Peng, X.X.; Kim, I.W.; Shukla, S.; Si, Q.S.; Robey, R.W.;Bates, S.E.; Shen, T.; Ashby, C.R. Jr; Fu, L.W.; Ambudkar, S.V.;Chen, Z.S. Erlotinib (Tarceva, OSI-774) antagonizes ATP-bindingcassette subfamily B member 1 and ATP-binding cassette subfamilyG member 2-mediated drug resistance. Cancer Res., 2007,67(22), 11012-11020. (Pubitemid 350145931)
83. Marchetti, S.; de Vries, N.A.; Buckle, T.; Bolijn, M.J.; vanEijndhoven, M.A.; Beijnen, J.H.; Mazzanti, R.; van Tellingen, O.;Schellens, J.H. Effect of the ATP-binding cassette drug transportersABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva)disposition in in vitro and in vivo pharmacokinetic studiesemploying Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-typemice. Mol. Cancer Ther., 2008, 7(8), 2280-2287.
84. McKillop, D.; McCormick, A.D.; Millar, A.; Miles, G.S.; Phillips,P.J.; Hutchison, M. Cytochrome P450-dependent metabolism ofgefitinib. Xenobiotica, 2005, 35(1), 39-50.
85. Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S.D. Differential metabolismof gefitinib and erlotinib by human cytochrome P450 enzymes.Clin. Cancer Res., 2007, 13(12), 3731-3737. (Pubitemid 46955138)
86. Hidalgo, M.; Bloedow, D. Pharmacokinetics and pharmacodynamics:maximizing the clinical potential of erlotinib (Tarceva). Semin.Oncol., 2003, 30, 25-33. (Pubitemid 36828625)
87. Herbst, R.S.; Khuri, F.R. Mode of action of docetaxel - a basis forcombination with novel anticancer agents. Cancer Treat. Rev.,2003, 29(5), 407-415. (Pubitemid 37185107)
88. García-Martín, E.; Pizarro, R.M.; Martínez, C.; Gutierrez-Martín,Y.; Pérez, G.; Jover, R.; Agúndez, J.A. Acquired resistance to theanticancer drug paclitaxel is associated with induction of cytochromeP45 2C8. Pharmacogenomic, 2006, 7(4), 575-585. (Pubitemid 43891414)
89. Schinkel, A.H.; Smit, J.J.; van Tellingen, O.; Beijnen, J.H.;Wagenaar, E.; van Deemter, L.; Mol, C.A.; van der Valk, M.A.;Robanus-Maandag, E.C.; te Riele, H.P.; Berns, A.J.M.; Borst, P.Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiencyin the blood-brain barrier and to increased sensitivity todrugs. Cell, 1994, 77(4), 491-502. (Pubitemid 24153990)
90. van Herwaarden, A.E.; Wagenaar. E.; van der Kruijssen, C.M.; vanWaterschoot, R.A.;, Smit, J.W.; Song, J.Y.; van der Valk, M.A.;van Tellingen, O.; van der Hoorn, J.W.; Rosing, H.; Beijnen, J.H.;Schinkel, A.H. Knockout of cytochrome P450 3A yields newmouse models for understanding xenobiotic metabolism. J. Clin.Invest., 2007, 117(11), 3583-3592. (Pubitemid 350097013)
91. Bardelmeijer, H.A.; Ouwehand, M.; Buckle, T.; Huisman, M.T.;Schellens, J.H.; Beijnen, J.H.; van Tellingen, O. Low systemic exposureof oral docetaxel in mice resulting from extensive first-passmetabolism is boosted by ritonavir. Cancer Res., 2002, 62(21),6158-6164. (Pubitemid 35244466)
92. Oostendorp, R.L.; Huitema, A.; Rosing, H.; Jansen, R.S.; TerHeine, R.; Keessen, M.; Beijnen, J.H.; Schellens, J.H. Coadministrationof ritonavir strongly enhances the apparent oral bioavailabilityof docetaxel in patients with solid tumors. Clin. Cancer Res.,2009, 15(12), 4228-4233.
93. Rochat, B. Role of cytochrome P450 activity in the fate of anticanceragents and in drug resistance: focus on tamoxifen, paclitaxeland imatinib metabolism. Clin. Pharmacokinet., 2005, 44(4), 349-366. (Pubitemid 40663682)
94. van Erp, N.P.; Gelderblom, H.; Guchelaar, H.J. Clinical pharmacokineticsof tyrosine kinase inhibitors. Cancer Treatment Reviews,2009, 35, 692-706.
95. Fujita K. Cytochrome P450 and anticancer drugs. Curr. Drug Metab.,2006, 7(1), 23-37.
96. van Schaik, R.H. Cancer treatment and pharmacogenetics of cytochromeP450 enzymes. Invest. New Drugs, 2005, 23(6), 513-522. (Pubitemid 43162470)
97. Zhou, S.F.; Di, Y.M.; Chan, E.; Du, Y.M.; Chow, V.D.; Xue, C.C.;Lai, X.; Wang, J.C.; Li, C.G.; Tian, M.; Duan, W. Clinical pharmacogeneticsand potential application in personalized medicine.Curr. Drug Metab., 2008, 9(8), 738-784.
98. Morjani, H.; Madoulet, C. Immunosuppressors as multidrug resistancereversal agents. Methods Mol. Biol., 2010, 596, 433-446.
99. Teft, W.A.; Mansell, S.E.; Kim, R.B. Endoxifen, the active metaboliteof tamoxifen, is a substrate of the efflux transporter pglycoprotein(multidrug resistance 1). Drug Metab. Dispos., 2011,39(3), 558-562.
100. Wu, L.; Xu, X.; Shen, J.; Xie, H.; Yu. S.; Liang, T.; Wang, W.;Shen, Y.; Zhang, M.; Zheng, S. MDR1 gene polymorphisms andrisk of recurrence in patients with hepatocellular carcinoma afterliver transplantation. J. Surg. Oncol., 2007, 96(1), 62-68. (Pubitemid 47015450)
101. Jamroziak, K.; Mlynarski, W.; Balcerczak, E.; Mistygacz, M.; Trelinska,M.; Mirowski, M.; Bodalski, J.; Robak, T. FunctionalC3435T polymorphism of MDR1 gene: an impact on genetic susceptibilityand clinical outcome of childhood acute lymphoblasticleukemia. Eur. J. Haematol., 2004, 72(5), 314-321. (Pubitemid 38520728)
102. Kim, D.H.; Park, J.Y.; Sohn, S.K.; Lee, N.Y.; Suh, J.S.; Lee, K.B.The association between multidrug resistance-1 gene polymorphismsand outcomes of allogeneic HLA-identical stem cell transplantation.Haematologica, 2006, 91(6), 848-651.
103. Wu, X.; Gu, J.; Wu, T.T.; Swisher, S.G.; Liao, Z.; Correa, A.M.;Liu, J.; Etzel, C.J.; Amos, C.I.; Huang, M.; Chiang, S.S.; Milas, L.;Hittelman, W.N.; Ajani, J.A.. Genetic variations in radiation andchemotherapy drug action pathways predict clinical outcomes inesophageal cancer. J. Clin. Oncol.; 2006, 24(23), 3789-3798. (Pubitemid 46628477)
104. Illmer, T.; Schuler, U.S.; Thiede, C.; Schwarz, U.I.; Kim, R.B.;Gotthard, S.; Freund, D.; Schäkel, U.; Ehninger, G.; Schaich, M.MDR1 gene polymorphisms affect therapy outcome in acute myeloidleukemia patients. Cancer Res., 2002, 62(17), 4955-4962. (Pubitemid 34984419)
105. Kim, D.H.; Park, J.Y.; Sohn, S.K.; Lee, N.Y.; Baek, J.H.; Jeon,S.B.; Kim, J.G.; Suh, J.S.; Do, Y.R.; Lee, K.B. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes inde novo acute myeloid leukemia. Int. J. Cancer, 2006, 118(9),2195-21201.
106. van den Heuvel-Eibrink, M.M.; Wiemer, E.A.; de Boevere, M.J.;van der Holt, B.; Vossebeld, P.J.; Pieters, R.; Sonneveld, P. MDR1gene-related clonal selection and P-glycoprotein function and expressionin relapsed or refractory acute myeloid leukemia. Blood,2001, 97(11), 3605-3611.
107. Hahn, N.M.; Marsh, S.; Fisher, W.; Langdon, R.; Zon, R.; Browning,M.; Johnson, C.S.; Scott-Horton, T.J.; Li, L.; McLeod, H.L.;Sweeney, C.J. Hoosier Oncology Group randomized phase II studyof docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survivalanalysis. Clin. Cancer Res., 2006, 12(20), 6094-6099. (Pubitemid 44703774)
108. Kim, D.H.; Sriharsha, L.; Xu, W.; Kamel-Reid, S.; Liu, X.; Siminovitch,K.; Messner, H.A.; Lipton, J.H. Clinical Relevance of aPharmacogenetic Approach Using Multiple Candidate Genes toPredict Response and Resistance to Imatinib Therapy in ChronicMyeloid Leukemia. Clin. Cancer Res., 2009, 15, 4750-4758.
109. Deenik, W.; van der Holt, B.; Janssen, J.J.; Chu, I.W.; Valk, P.J.;Ossenkoppele, G.J.; van der Heiden, I.P.; Sonneveld, P.; vanSchaik, R.H.; Cornelissen, J.J. Polymorphisms in the multidrug resistancegene MDR1 (ABCB1) predict for molecular resistance inpatients with newly diagnosed chronic myeloid leukemia receivinghigh-dose imatinib. Blood, 2010, 116(26), 6144-6145.
110. Bray, J.; Sludden, J.; Griffin, M.J.; Cole, M.; Verrill, M.; Jamieson,D.; Boddy, A.V. Influence of pharmacogenetics on response andtoxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.Br. J. Cancer, 2010, 102(6), 1003-1009.